Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese pharma giant’s tyrosine kinase inhibitor Lenvima for a certain type of cancer in the gastrointestinal tract.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the adrenal glands.

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.